About FTDZX
Franklin Biotechnology Discovery Fund Advisor Class is a mutual fund that focuses on delivering capital appreciation by investing primarily in the biotechnology sector. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms—enterprises that derive a significant portion of their revenue from biotechnology-related activities. The fund’s portfolio often includes both established and emerging biotechnology firms, with a notable allocation to smaller capitalization companies, typically those with market values below $2 billion at the time of investment. While the fund maintains a majority exposure to U.S.-based companies, it may allocate up to 20% of its assets to foreign securities, including American, European, and Global Depositary Receipts. Managed using a fundamental, research-driven investment approach, the fund seeks out companies with identifiable drivers of future earnings growth and sustainable growth characteristics. Franklin Biotechnology Discovery Fund Advisor Class plays a significant role in offering investors a specialized vehicle for gaining exposure to innovations and growth opportunities within the global biotechnology industry, reflecting both the sector’s risk profile and potential for long-term growth.
Fund Family Franklin Templeton Investments
Category Health
Performance Rating Above Average
Risk Rating Above Average
Stock Exchange NASDAQ
Ticker Symbol FTDZX
Share Class Advisor Class
Index NASDAQ Biotechnology CR
FTDZX had a total return of 75.91% in the past year, including dividends.
Since the fund's inception, the average annual return has been 12.81%.
